Pasithea Therapeutics (KTTA) Depreciation & Amortization (CF) (2022 - 2025)
Pasithea Therapeutics recorded quarterly Depreciation & Amortization (CF) of $17000.0 in Q4 2025, down 65.31% quarter-over-quarter from $49000.0 in Q3 2025, and up 250.37% year-over-year from $4852.0 in Q4 2024.
Pasithea Therapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $17000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 250.37% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $70000.0 (up 255.82% YoY), while the FY2025 annual figure was $49000.0, up 157.89% from the prior year.
- Depreciation & Amortization (CF) came in at $17000.0 for Q4 2025 at Pasithea Therapeutics, down from $49000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $49000.0 in Q3 2025 to a low of $4000.0 in Q2 2025.
- A 4-year average of $9330.6 and a median of $4836.5 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) tumbled 71.72% in 2023 and surged 880.0% in 2025, its largest moves.
- Pasithea Therapeutics' Depreciation & Amortization (CF) stood at $4138.0 in 2022, then increased by 13.1% to $4680.0 in 2023, then gained by 3.68% to $4852.0 in 2024, then surged by 250.37% to $17000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $17000.0, $49000.0, and $4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,166.00 |
| Mar 31, 2025 | 4,166.00 |
| Dec 31, 2024 | 4,852.00 |
| Dec 31, 2024 | 4,852.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 4,717.00 |
| Mar 31, 2024 | 4,717.00 |
| Dec 31, 2023 | 4,680.00 |
| Dec 31, 2023 | 4,680.00 |
| Sep 30, 2023 | 4,715.00 |
| Sep 30, 2023 | 4,715.00 |
| Jun 30, 2023 | 4,716.00 |
| Jun 30, 2023 | 4,716.00 |
| Mar 31, 2023 | 4,179.00 |
| Mar 31, 2023 | 4,179.00 |
| Dec 31, 2022 | 4,138.00 |
| Dec 31, 2022 | 4,138.00 |
| Sep 30, 2022 | 16,670.00 |
| Sep 30, 2022 | 16,670.00 |
| Jun 30, 2022 | 10,787.00 |
| Jun 30, 2022 | 10,787.00 |
| Mar 31, 2022 | 5,014.00 |
| Mar 31, 2022 | 5,014.00 |